Literature DB >> 19753487

Protective immunity against Trypanosoma cruzi.

Cecilia Parodi1, Angel Marcelo Padilla, Miguel Angel Basombrío.   

Abstract

Upon infection, Trypanosoma cruzi triggers a strong immune response that has both protective and pathological consequences. In this work, several important questions regarding protective immunity are reviewed. Emphasis is placed on recent studies of the important protective role of CD8+ T cells and on previous studies of immunisation of domestic T. cruzi reservoirs that sought to address practical vaccination problems. Research on the maturation of memory cells and studies indicating that the prevalence of T. cruzi-specific T-cell responses and a high frequency of committed CD8+ T cells are associated with better clinical outcomes are also reviewed. Additionally, animal models in which protection was achieved without immunopathological consequences are discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19753487     DOI: 10.1590/s0074-02762009000900038

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  9 in total

Review 1.  Advances and challenges towards a vaccine against Chagas disease.

Authors:  Israel Quijano-Hernandez; Eric Dumonteil
Journal:  Hum Vaccin       Date:  2011-11-01

Review 2.  Importance of nonenteric protozoan infections in immunocompromised people.

Authors:  J L N Barratt; J Harkness; D Marriott; J T Ellis; D Stark
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

3.  The centennial of the discovery of Chagas disease: facing the current challenges.

Authors:  Joseli Lannes-Vieira; Tania C de Araújo-Jorge; Maria de Nazaré Correia Soeiro; Paulo Gadelha; Rodrigo Corrêa-Oliveira
Journal:  PLoS Negl Trop Dis       Date:  2010-06-29

4.  MIF synergizes with Trypanosoma cruzi antigens to promote efficient dendritic cell maturation and IL-12 production via p38 MAPK.

Authors:  Cesar A Terrazas; Erik Huitron; Alicia Vazquez; Imelda Juarez; Griselda M Camacho; Elsa A Calleja; Miriam Rodriguez-Sosa
Journal:  Int J Biol Sci       Date:  2011-10-25       Impact factor: 6.580

5.  A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy.

Authors:  Isabela Resende Pereira; Glaucia Vilar-Pereira; Virgínia Marques; Andrea Alice da Silva; Bráulia Caetano; Otacilio Cruz Moreira; Alexandre Vieira Machado; Oscar Bruna-Romero; Maurício Martins Rodrigues; Ricardo Tostes Gazzinelli; Joseli Lannes-Vieira
Journal:  PLoS Pathog       Date:  2015-01-24       Impact factor: 6.823

6.  Epidemiological modeling of Trypanosoma cruzi: Low stercorarian transmission and failure of host adaptive immunity explain the frequency of mixed infections in humans.

Authors:  Nicolás Tomasini; Paula Gabriela Ragone; Sébastien Gourbière; Juan Pablo Aparicio; Patricio Diosque
Journal:  PLoS Comput Biol       Date:  2017-05-08       Impact factor: 4.475

7.  Vaccination using recombinants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on protection against Trypanosoma cruzi infection.

Authors:  Rafael Polidoro Alves Barbosa; Bruno Galvão Filho; Luara Isabela Dos Santos; Policarpo Ademar Sales Junior; Pedro Elias Marques; Rafaela Vaz Sousa Pereira; Denise Carmona Cara; Oscar Bruña-Romero; Maurício Martins Rodrigues; Ricardo Tostes Gazzinelli; Alexandre Vieira Machado
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

8.  CpG and interleukin-15 synergize to enhance IFN-γ production by activated CD8+ T cells.

Authors:  Dustin Cobb; Siqi Guo; Ronald B Smeltz
Journal:  Biomed Res Int       Date:  2012-12-23       Impact factor: 3.411

9.  A Novel Vaccine Approach for Chagas Disease Using Rare Adenovirus Serotype 48 Vectors.

Authors:  Anitra L Farrow; Binghao J Peng; Linlin Gu; Alexandre Krendelchtchikov; Qiana L Matthews
Journal:  Viruses       Date:  2016-03-10       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.